Abrégé

The present disclosure relates to methods and products for identifying conditions associated with cardiac fibrotic remodelling. Certain embodiments of the present disclosure provide a method of identifying a subject suffering from, or susceptible to, a condition associated with cardiac fibrotic remodelling, the method comprising identifying an increased level of follistatin-like 3 in the subject.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
• G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present disclosure relates to methods and products for preventing and/or treating autoimmune diseases. Certain embodiments of the present disclosure provide a method of preventing and/or treating an autoimmune disease in a subject, the method comprising exposing the subject to immunomodulatory cells expressing one or more auto-inflammatory homing chemokine receptors, and/or depleting and/or inactivating CCR2+T helper cells, IL-23R+ T helper cells and/or IL- 1R+ T helper cells in the subject, and thereby preventing and/or treating the autoimmune disease in the subject.

Classes IPC  ?

• A61K 35/17 - Lymphocytes; Lymphocytes B; Lymphocytes T; Cellules tueuses naturelles; Lymphocytes activés par un interféron ou une cytokine
• A61K 35/28 - Moelle osseuse; Cellules souches hématopoïétiques; Cellules souches mésenchymateuses de toutes origines, p.ex. cellules souches dérivées de tissu adipeux
• A61K 39/395 - Anticorps; Immunoglobulines; Immunsérum, p.ex. sérum antilymphocitaire
• A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
• C12N 5/0783 - Cellules T; Cellules NK; Progéniteurs de cellules T ou NK
• C07K 16/46 - Immunoglobulines hybrides
• C07K 14/725 - Récepteurs de lymphocytes-T

Abrégé

The present disclosure relates to methods and products for preventing and/or treating atrial fibrillation. Certain embodiments of the present disclosure provide a method for preventing and/or treating atrial fibrillation in a subject, the method comprising administering to the subject a therapeutically effective amount of an endothelin receptor antagonist.

Classes IPC  ?

• A61K 31/506 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime non condensées et contenant d'autres hétérocycles
• A61K 31/4025 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p.ex. sulpiride, succinimide, tolmétine, buflomédil non condensés et contenant d'autres hétérocycles, p.ex. cromakalim
• A61P 9/06 - Antiarythmiques

Abrégé

A method and system for assessing the condition of a pipeline in a pipeline system is disclosed. The method includes generating a pressure wave in the fluid being carried along the pipeline system at a pressure wave generating location along the pipeline system and detecting pressure wave interaction signals at two closely spaced measurement locations along the pipeline. The method then includes determining a system response function for the pipeline based on the detected pressure wave interaction signals for each measurement location and characterising the pipeline based on the system response function.

Classes IPC  ?

• G01M 3/28 - Examen de l'étanchéité des structures ou ouvrages vis-à-vis d'un fluide par utilisation d'un fluide ou en faisant le vide par mesure du taux de perte ou de gain d'un fluide, p.ex. avec des dispositifs réagissant à la pression, avec des indicateurs de débit pour soupapes
• G01L 15/00 - Dispositifs ou appareils pour la mesure simultanée de plusieurs valeurs de la pression des fluides
• G01L 13/00 - Dispositifs ou appareils pour la mesure des différences entre plusieurs valeurs de la pression des fluides
• F17D 5/02 - Prévention, interception ou localisation des pertes

Abrégé

The present disclosure relates to methods and products for enriching and isolating stromal stem cells. Certain embodiments of the present disclosure provide a method of enriching for immature, uncommitted stromal stem cells from a population of cells comprising stromal stem cells, the method comprising enriching stromal stem cells from the population of cells using a HSC70 binding agent.

Classes IPC  ?

• C12N 5/07 - Cellules animales ou tissus animaux
• C12N 5/0775 - Cellules souches mésenchymateuses; Cellules souches dérivées du tissu adipeux
• C12N 5/074 - Cellules souches adultes
• C12N 5/071 - Cellules ou tissus de vertébrés, p.ex. cellules humaines ou tissus humains
• A61K 35/28 - Moelle osseuse; Cellules souches hématopoïétiques; Cellules souches mésenchymateuses de toutes origines, p.ex. cellules souches dérivées de tissu adipeux
• C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides

Abrégé

The present invention provides composite material having a porous graphene-based foam matrix and comprising porous inorganic micro-particles and metal oxide nano-particles distributed throughout the foam matrix.

Classes IPC  ?

• B01J 20/20 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtration; Absorbants ou adsorbants pour la chromatographie; Procédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant du carbone obtenu par des procédés de carbonisation
• B01J 20/28 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtration; Absorbants ou adsorbants pour la chromatographie; Procédés pour leur préparation, régénération ou réactivation caractérisées par leur forme ou leurs propriétés physiques
• C01B 31/04 - Graphite
• B01D 15/00 - Procédés de séparation comportant le traitement de liquides par des adsorbants ou des absorbants solides; Appareillages pour ces procédés

Abrégé

The present disclosure relates to methods and systems for determining the risk of a complication of pregnancy occurring. Certain embodiments of the present disclosure provide a method of determining the risk of a complication of pregnancy occurring in a subject, the pregnancy arising in the subject from a conception from a maternal donor and a paternal donor. The method comprises receiving initial information comprising (i) initial genetic information and/or (ii) initial clinical information and/or (iii) initial lifestyle information, the initial information being from the subject and/or the maternal donor and/or the paternal donor; processing the initial information to classify the risk of a complication of pregnancy occurring in the subject as low risk or increased risk; for the subject having said increased risk, receiving further information, the further information comprising (i) further genetic information and/or (ii) further clinical information and/or (iii) further lifestyle information from the subject and/or the maternal donor and/or the paternal donor; processing the further information to classify the risk in the subject having said increased risk as moderate risk or high risk, thereby determining the risk of a complication of pregnancy occurring in the subject.

Classes IPC  ?

• G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p.ex. pour des dossiers électroniques de patients

Abrégé

The present invention relates to a biomarker for early stage ovarian cancer. Specifically, expression of the biomarker Annexin A2 is higher in the plasma of subjects with early stage ovarian cancer. Accordingly, methods of detecting early stage ovarian cancer in a subject, of identifying a subject having early stage ovarian cancer, and of determining if a subject is susceptible to developing ovarian cancer, are provided. Also provided are methods of screening candidate therapeutic agents for use in treating early stage ovarian cancer, and compositions and kits for detecting early stage ovarian cancer in a subject, for identifying a subject having early stage ovarian cancer, and for determining if a subject is susceptible to developing ovarian cancer.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
• G01N 33/574 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour le cancer

Abrégé

The present disclosure relates to methods, compositions and products for modulating osteogenesis and/or angiogenesis by modulating peroxidase functionality. Certain embodiments provide a method of modulating osteogenesis and/or angiogenesis in a subject, the method comprising administering to the subject an effective amount of an agent that modulates peroxidase functionality, thereby modulating osteogenesis and/or angiogenesis in the subject.

Classes IPC  ?

• A61K 38/44 - Oxydoréductases (1) 
• A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
• A61P 19/00 - Médicaments pour le traitement des troubles du squelette
• A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques 
• A61K 38/00 - Préparations médicinales contenant des peptides
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

A method for preventing, treating and/or reversing a disease, condition or state in a subject in need thereof by administering to the subject an effective amount of the (-)-perhexiline or a pharmaceutically acceptable salt, prodrug or derivative thereof, substantially free of (+)- perhexiline, or a pharmaceutical composition containing same. The diseases, components, features, conditions or states are associated with, caused by, manifesting, or resulting in, a reduced cellular redox state, hypoxia, an undesired lactic acid production or lactate utilization, and/or lactic acidosis.

Classes IPC  ?

• A61K 31/4458 - Pipéridines non condensées, p.ex. pipérocaïne substituées uniquement en position 2, p.ex. méthylphénidate
• A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
• A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
• A61P 31/00 - Agents anti-infectieux, c. à d. antibiotiques, antiseptiques, chimiothérapeutiques
• A61P 33/00 - Agents antiparasitaires

Abrégé

A method for extracting plant nucleic acids from lignified plant tissue comprising the steps of: a) exposing the lignified plant tissue to a solution comprising: a cationic surfactant, boric acid and buffer to extract the nucleic acids; b) purifying the nucleic acids extracted in (a).

Classes IPC  ?

• C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN

Abrégé

The present disclosure provides an optical sensor that comprises an optical waveguide. The optical waveguide has a first portion that comprises an optical material that is arranged such that, when the material is exposed to suitable electromagnetic radiation (EMR), the optical material absorbs at least a portion of the suitable EMR and emits emission EMR and a property of the emission EMR is dependent on a temperature of the optical material. The optical waveguide further comprises a second portion for guiding the emission EMR from the first portion. The optical sensor is arranged such that a temperature of only the first portion affects the property of the emission EMR.

Classes IPC  ?

• G01K 11/32 - Mesure de la température basée sur les variations physiques ou chimiques, n'entrant pas dans les groupes , , ou utilisant des changements dans la transmittance, la diffusion ou la luminescence dans les fibres optiques

Abrégé

A hybrid solar and chemical looping combustion system (10) comprising a fuel reactor (11), an air reactor (12), a looping path (13) for transferring looping material comprising oxygen carrier particles (15) between the fuel reactor (11) and the air reactor (12). The fuel reactor (11) is configured to be heated by concentrated solar energy. First and second reservoirs (41, 42) are provided in the looping path (13) for receiving looping material. The first reservoir (41) is disposed between the air reactor (12) and the fuel reactor (11), and the second reservoir (42) is disposed between the fuel reactor (11) and the air reactor (12). A heat exchanger (45) is provided in the looping path (13) in the between the air reactor (12) and the first reservoir (41) for heat transfer from the looping material (13) to an air flow to the air reactor (12). The heat exchanger (45) may comprise a direct air-particle heat exchanger. A system for generation of power comprising the hybrid solar and chemical looping combustion system (10) is also descried. Further, a method of generating power using the hybrid solar and chemical looping combustion system (10) is also described.

Classes IPC  ?

• F23C 9/00 - Appareils à combustion caractérisés par des dispositions pour renvoyer les produits de combustion ou les gaz de fumée dans la chambre de combustion
• F03G 6/06 - Dispositifs produisant une puissance mécanique à partir d'énergie solaire avec des moyens de concentration de l'énergie solaire
• F24S 90/00 - Systèmes à chaleur solaire non prévus ailleurs

Abrégé

The present invention relates to the identification of biological markers of ovarian cancer. Specifically, cancer-associated autoantibodies to ANXA1, ARP3, SAHH, SERPH, ARAP1, OTUB1, ATP1A1, UBA1, and CFAH have been identified in subjects with early stage ovarian cancer. These autoantibodies can be utilised for a range of purposes including methods for detecting ovarian cancer, methods for screening for early stage ovarian cancer, and methods for assessing treatment response as well as disease progression and recurrence. The autoantibodies also represent prognostic markers of ovarian cancer development.

Classes IPC  ?

• G01N 33/574 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour le cancer
• C07K 16/00 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux
• C07K 16/30 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
• C07K 16/44 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel non prévu ailleurs

Abrégé

The present invention relates to a method of detecting a change in intracellular calcium flax of a cell by (i) providing a platform comprising a surface to which is bound an at least one ligand that binds with, the cell and induces a change in the intracellular calcium flux of the cell; (ii) contacting the surface with a fluid sample comprising the cell under conditions suitable for the at least one ligand to bind with the cell such that the cell is captured by the platform, and wherein binding of the at least one ligand with the cell induces a change in the intracellular calcium flux of the cell; and (iii) detecting the change in a parameter of intracellular calcium flux of the cell in a continuous manner. Method of determining magnitude of cell activation and use of said method to determine vaccine efficacy or to assess an immune response are also provided.

Classes IPC  ?

• G01N 33/84 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des composés inorganiques ou le pH
• C12N 5/0783 - Cellules T; Cellules NK; Progéniteurs de cellules T ou NK

Abrégé

The present invention relates to mastitis and to the identification of factors that play a role in the aetiology and progression of mastitis. In particular, an association between mastitis and toll-like receptors has been identified. The present invention therefore provides, amongst other things, methods for the treatment and prevention of mastitis, improving lactation in a mastitis affected subject, and/or treating and/or preventing mammary tissue damage in a mastitis affected subject, by inhibiting the activity of at least one toll-like receptor in the subject.

Classes IPC  ?

• A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques 
• A61K 38/00 - Préparations médicinales contenant des peptides
• A61K 39/395 - Anticorps; Immunoglobulines; Immunsérum, p.ex. sérum antilymphocitaire
• A61P 31/04 - Agents antibactériens
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]

Abrégé

A dual wavelength pumping system and method have been developed to improve die efficiency of laser systems operating in the raid infrared region has been developed, in a conventional system the ions are excited from a ground state to an upper lasing state using a light pump. They then undergo a laser transition to leave the ion in a long lived post lasing excited state from which it eventually decays back to the ground state. In contrast they present system uses a first light pump to pump ions from the ground state to the post lasing state, and a second light pump to pump ions from the post lasing state to the upper lasing state. This system thus exploits the long lifetime of the post lasing state to enable it to become a virtual ground state for the second laser allowing continued cycling of ions between the upper lasing state and the post lasing state. A system using an Erbium, doped fibre generated a 3.5 μm laser output with an average power of over 250mW and an initial slope, efficiency of 25.4% (previous system have only generates less than 10mW of power with efficiencies of 3%).

Classes IPC  ?

• H01S 3/091 - Procédés ou appareils pour l'excitation, p.ex. pompage utilisant le pompage optique

Abrégé

The present disclosure relates to methods and compositions for inducing an immune response to a selected antigen in a subject. Certain embodiments of the present disclosure provide a method of inducing an immune response to a selected antigen in a subject, the method comprising inhibiting activity of a chemokine receptor CCX-CKR in the subject and exposing the subject to the selected antigen.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/395 - Anticorps; Immunoglobulines; Immunsérum, p.ex. sérum antilymphocitaire
• A61P 37/02 - Immunomodulateurs
• A61P 35/00 - Agents anticancéreux
• C07K 16/24 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens

Abrégé

Herbicide resistant barley plants and compositions and methods for producing herbicide resistant barley hybrids, in particular barley plants with mutated acetyl-CoA carboxylase (ACCase) genes that are resistant to ACCase inhibiting herbicides, such as barley varieties BOZO and HT107.

Classes IPC  ?

• C12N 15/29 - Gènes codant pour des protéines végétales, p.ex. thaumatine
• C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
• C12N 15/01 - Préparation de mutants sans introduction de matériel génétique étranger; Procédés de criblage à cet effet
• A01H 3/04 - Procédés de modification des phénotypes par traitement au moyen de produits chimiques
• A01H 5/00 - Angiospermes, c. à d. plantes à fleurs, caractérisées par leurs parties végétales; Angiospermes caractérisées autrement que par leur taxonomie botanique

Abrégé

The invention relates to methods and agents for modulating the binding or responsiveness of GABA to the GABA-responsive motif of ALMT in plants.

Classes IPC  ?

• C07K 14/415 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de végétaux

Abrégé

The present invention relates to novel macrocyclic compounds of Formula I and their use as novel therapeutic agents for example as novel compounds used in methods of preventing and/or treating a disease, condition or state in a subject associated with dysregulation of protease activity and/or dysregulation of proteosome activity

Classes IPC  ?

• C07D 487/16 - Systèmes condensés en péri
• C07D 491/06 - Systèmes condensés en péri
• C07D 491/22 - Composés hétérocycliques contenant dans le système cyclique condensé, à la fois un ou plusieurs cycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle, et un ou plusieurs cycles comportant des atomes d'azote comme uniques hétéro- dans lesquels le système condensé contient au moins quatre hétérocycles
• A61K 31/407 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p.ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des systèmes hétérocycliques, p.ex. kétorolac, physostigmine
• A61P 31/12 - Antiviraux
• A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
• A61P 35/00 - Agents anticancéreux
• A61P 25/06 - Agents antimigraineux

Abrégé

The present disclosure relates to methods and products for preventing and/or treating a stress- induced cardiomyopathy. Certain embodiments of the present disclosure provide a method of preventing and/or treating a stress-induced cardiomyopathy in a subject, the method comprising administering to the subject a therapeutically effective amount of one or more of the following agents: a peroxynitrite inhibitor; an inhibitor of peroxynitrite synthesis; an inhibitor of peroxynitrite associated signalling; an inhibitor of peroxynitrite-induced DNA damage; a Tx NIP inhibitor; a beta 2 adrenoceptor antagonist; and a beta 3 adrenoceptor antagonist; thereby preventing and/or treating the stress-induced cardiomyopathy in the subject.

Classes IPC  ?

• A61K 31/166 - Amides, p.ex. acides hydroxamiques ayant des cycles aromatiques, p.ex. colchicine, aténolol, progabide ayant l'atome de carbone d'un groupe carboxamide lié directement au cycle aromatique, p.ex. procaïnamide, procarbazine, métoclopramide, labétalol
• A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire

Abrégé

The present disclosure provides a device for characterising a chromatic property of foodstuff. The device comprises a light source arranged to emit light having at least two wavelengths or wavelength ranges. The light source is further arranged to direct the light to a surface of at least the foodstuff. The device also comprises a detector positioned to detect at least a portion of reflected light and arranged to generate an output that is indicative of an intensity of detected reflected light. The device is arranged such that respective outputs are generated for the at least two wavelengths or wavelength ranges. A relation between the output for one of the at least two wavelengths or wavelength ranges and the output for the other or another one of the at least two wavelengths or wavelength ranges is indicative of the chromatic property of the surface of the foodstuff.

Classes IPC  ?

• A47J 37/08 - Grille-pain
• G01N 21/17 - Systèmes dans lesquels la lumière incidente est modifiée suivant les propriétés du matériau examiné

Abrégé

The present disclosure relates to the prevention and/or treatment of metastatic cancer. Certain example embodiments of the present disclosure provide a method for preventing and/or treating a metastatic cancer in a subject. The method comprises administering to the subject a therapeutically effective amount of an inhibitor of a chemokine receptor CCX-CKR.

Classes IPC  ?

• A61K 39/395 - Anticorps; Immunoglobulines; Immunsérum, p.ex. sérum antilymphocitaire
• A61K 31/7105 - Acides ribonucléiques naturels, c. à d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester 
• A61P 35/00 - Agents anticancéreux
• A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
• G01N 33/53 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet
• C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C07K 16/30 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
• C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées

Abrégé

The present disclosure relates to the use of the (-) enantiomer of perhexiline (2-(2,2-dicyclohexylethyl)piperidine) for preventing and/or treating a disease, condition or state associated with altered tissue energetics, such as altered myocardial metabolism associated with cardiovascular related disease states. Certain example embodiments of the present disclosure provide a method for preventing and/or treating a disease, condition or state associated with altered tissue energetics in a subject in need thereof. The method comprises administering to the subject an effective amount of the (-)-enantiomer of perhexiline and/or a pharmaceutically acceptable salt, prodrug or derivative thereof, substantially free of the other enantiomer.

Classes IPC  ?

• A61K 31/445 - Pipéridines non condensées, p.ex. pipérocaïne
• A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p.ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénal
• A61P 9/04 - Agents inotropes, c. à d. stimulants de la contraction cardiaque; Médicaments pour le traitement de l'insuffisance cardiaque

Abrégé

This invention relates to a wing comprising a generally aerofoil (or airfoil) shaped body having a leading edge, a trailing edge, a span, and first and second major surfaces extending between the leading edge and the trailing edge, where at least one of said first or second major surfaces comprises cyclic spanwise variations at or near the leading edge thereof, but not the trailing edge thereof. In preference, the cyclic spanwise variations extend substantially chordwise from at or near the leading edge, progressively diminishing as they extend chordwise so as to disappear at or before reaching the trailing edge of the wing.

Classes IPC  ?

• B64C 3/10 - Forme des ailes
• B64C 21/00 - Moyens permettant d'influencer l'écoulement d'air sur les surfaces des aéronefs en agissant sur la couche limite
• F03D 1/06 - Rotors
• F03D 3/06 - Rotors
• B64C 11/18 - Caractéristiques aérodynamiques
• B64C 27/467 - Caractéristiques aérodynamiques
• F04D 29/24 - Aubes
• F03B 3/14 - Rotors à aubes réglables

Abrégé

The present disclosure relates generally to polysaccharide synthases. The present disclosure reveals that a subset of the CesA gene family encode XynS xylan synthases. As a result of the identification of XynS nucleic acids, and corresponding amino acid sequences that encode XynS xylan synthases, the present invention provides, inter alia, methods and compositions for modulating the level and/or activity of xylan synthase in a cell and/or modulating the level of xylan produced by a cell.

Classes IPC  ?

• C12N 15/54 - Transférases (2)
• C12N 9/10 - Transférases (2.)
• C08B 37/14 - Hémicellulose; Ses dérivés

Abrégé

The invention, in one aspect, provides a system for determining movement. The system comprises at least one receiving module arranged to receive movement data indicative of movement from a remote device, a processing module arranged to process the moving data to determine the type of movement, and an alert module arranged to provide an alert in the event that the type of movement falls within at least one predetermined type.

Classes IPC  ?

• G01P 15/00 - Mesure de l'accélération; Mesure de la décélération; Mesure des chocs, c. à d. d'une variation brusque de l'accélération
• A61B 5/11 - Mesure du mouvement du corps entier ou de parties de celui-ci, p.ex. tremblement de la tête ou des mains ou mobilité d'un membre

Abrégé

The present invention relates to methods of inducing or enhancing an immune response against an immunogen in a subject. The invention further includes isolated nucleic acid vaccines, cellular vaccines, fusion proteins, expression vectors, vaccines, and immunogenic compositions for use therein.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/21 - Retroviridae, p.ex. virus de l'anémie infectieuse équine
• A61K 39/29 - Virus de l'hépatite
• A61K 31/711 - Acides désoxyribonucléiques naturels, c. à d. contenant uniquement des 2'-désoxyriboses liés à l'adénine, la guanine, la cytosine ou la thymine et ayant des liaisons 3'-5' phosphodiester
• A61P 37/04 - Immunostimulants
• C12N 5/0784 - Cellules dendritiques; Leurs progéniteurs
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion

Abrégé

A hybrid receiver-combustor (100) for capturing heat energy from a solar source and a fuel source. The hybrid receiver-combustor (100) includes a vessel (110) for acting both as a combustion furnace and as a solar receiver, and a plurality of burners (180) for combusting an oxidant stream, such as an air stream, and a fuel stream. The vessel (110) includes a casing (120) defining a cavity (125) having an aperture (130) for receiving the concentrated solar radiation from the solar source. The cavity (125) provides a chamber defining a zone (126) which can function as a combustion zone for production of heat energy through a combustion process using the fuel and into which concentrated solar radiation can be received from the solar source through the aperture (130). A heat energy absorber (190) configured as a heat exchanger is provided to receive heat energy from concentrated solar radiation entering the cavity (125) through the aperture (130) and from combustion within the cavity. A fluidic seal system (135) is associated with the aperture (130) and is operable to establish a fluidic seal to restrict fluid flow through the aperture (130) during the combustion process. The fluidic seal comprises exhaust gas from the combustion process within the cavity (125).

Classes IPC  ?

• F24J 2/04 - Collecteurs de chaleur solaire avec fluide vecteur circulant à travers le collecteur
• F03G 6/00 - Dispositifs produisant une puissance mécanique à partir d'énergie solaire

Abrégé

The present disclosure relates to methods for identifying a cardiac region for ablation, methods of treating a subject susceptible to or suffering from a cardiac arrhythmia, systems for identifying a cardiac region for ablation and computer-readable media. Certain embodiments provide a method of identifying a cardiac region for ablation to prevent and/or treat a cardiac arrhythmia, the method comprising determining one or more electrical waveform characteristics at a plurality of cardiac sites, identifying a cardiac region of maximal variance of the one or more electrical waveform characteristics, and identifying the cardiac region of maximal variance of the one or more electrical waveform characteristics as the cardiac region for ablation to prevent and/or treat the cardiac arrhythmia.

Classes IPC  ?

• A61B 5/046 - Détection de la fibrillation
• A61B 5/0472 - Détection de complexes QRS anormaux
• A61B 5/0402 - Electrocardiographie, c. à d. ECG
• A61B 5/0468 - Détection d'intervalle ECG anormal
• A61N 1/37 - Surveillance; Protection
• A61N 1/39 - Défibrillateurs cardiaques

Abrégé

The present invention provides biological markers associated with gastric cancer. In particular, the present invention provides a method of diagnosing gastric cancer (GC) in a subject, the method including: measuring an expression level of one or more proteins in the subject, wherein the one or more proteins are selected from the group consisting of vitamin D binding protein (VDBP), clusterin, insulin like growth factor binding protein complex acid labile subunit (IGFALS), and afamin; comparing the expression level of the or each protein in the subject to a reference expression level for the or each protein; and diagnosing GC in the subject on the basis of the comparison. On the basis of the identification of biological markers associated with gastric cancer, the present invention also provides a method of determining if a subject is susceptible to developing gastric cancer, a method of assessing progression of gastric cancer in a subject, a method for screening a candidate therapeutic agent useful for treating gastric cancer in a subject, and a kit for diagnosing gastric cancer in a subject.

Classes IPC  ?

• G01N 33/574 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour le cancer
• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The invention relates to a method for stabilising fatty acids present in a sample such as bodily fluids (e.g. blood, saliva, breast milk, urine, semen, blood plasma and serum), using a solid medium (such as paper, a glass-based matrix, a paper-based matrix, a cellulose-based matrix, hydrophilic polymers, polytetrafluoroethylene, fibreglass and porous ceramics) comprising chelating agents (e.g. ethylenediamine-tetraacetic acid, ascorbic acid, citric acid, or salts thereof), antioxidants (e.g. butylated hydroxytoluene, butylated hydroxyanisole or t-butylhydroquinone) and less than than about 2 μg/cm2 of contaminants which is capable of stabilising fatty acids applied thereto, and a method for preparing such media. The invention further relates to a method for determining the fatty acid composition of a sample stored on such a medium.

Classes IPC  ?

• G01N 30/50 - Conditionnement de l'absorbant ou de l'adsorbant ou de la phase liquide stationnaire
• G01N 33/48 - Matériau biologique, p.ex. sang, urine; Hémocytomètres
• G01N 33/92 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des lipides, p.ex. le cholestérol
• A61B 5/15 - Dispositifs de prélèvement d'échantillons de sang
• C11B 5/00 - Conservation par emploi d'additifs, p.ex. d'antioxydants
• G01N 1/36 - Enrobage ou montage analogue d'échantillons

Abrégé

The present disclosure relates to a method of improving developmental competence of an oocyte. The method comprises exposing the oocyte and/or an embryo to an endoplasmic reticulum stress inhibitor and/or an inducer of heat shock proteins.

Classes IPC  ?

• C12N 5/075 - Oocytes; Oogonies
• A61P 15/08 - Médicaments pour le traitement des troubles génitaux ou sexuels; Contraceptifs pour les troubles gonadiques ou pour augmenter la fertilité, p.ex. inducteurs d'ovulation ou de spermatogénèse

Abrégé

A new class of biotin protein ligase (BPL) inhibitors that have antibacterial activity against multiple Staphylococcus aureus isolates, including clinically important methicillin-resistant S. aureus (MRSA) are disclosed that are non-toxic.

Classes IPC  ?

• C07D 495/04 - Systèmes condensés en ortho
• A61K 31/4188 - 1,3-Diazoles condensés avec des systèmes hétérocycliques, p.ex. biotine, sorbinil
• A61P 31/04 - Agents antibactériens

Abrégé

An immunogenic composition, that may be a vaccine comprising GlpO or a fragment thereof suitable for use in the treatment or prevention of a streptococcal infection, in particular meningitis. The GlpO or fragment thereof is preferably enzymatically inactive. In a preferred form immunogenic comprises additionally a further immunogen known to be protective against steptococcal infection which further immunogen is preferably a protein. One particularly illustrated such further protein is a non-toxic pneumolysin.

Classes IPC  ?

• A61K 38/44 - Oxydoréductases (1) 
• A61K 38/02 - Peptides à nombre indéterminé d'amino-acides; Leurs dérivés
• A61K 39/40 - Anticorps; Immunoglobulines; Immunsérum, p.ex. sérum antilymphocitaire bactériens
• A61P 31/04 - Agents antibactériens

Abrégé

A system for characterising a material is provided. The system comprises an optical sensor comprising an optical waveguide, the optical waveguide having first and second ends and being characterised by having a numerical aperture greater than or equal to 0.2, and a microresonator comprising an optically active material, the microresonator being positioned in an optical near field of an end face of the first end of the optical waveguide such that the optically active material is excitable by light. The system further comprises a light source for exciting the optically active material of the microresonator so as to generate whispering gallery modes (WGMs) in the microresonator and a light collector for collecting an intensity of light that is associated with the WGMs excited in the microresonator.

Classes IPC  ?

• G02B 6/00 - OPTIQUE ÉLÉMENTS, SYSTÈMES OU APPAREILS OPTIQUES - Détails de structure de dispositions comprenant des guides de lumière et d'autres éléments optiques, p.ex. des moyens de couplage
• G01N 21/00 - Recherche ou analyse des matériaux par l'utilisation de moyens optiques, c. à d. en utilisant des ondes submillimétriques, de la lumière infrarouge, visible ou ultraviolette
• A61B 5/1459 - Mesure des caractéristiques du sang in vivo, p.ex. de la concentration des gaz dans le sang, de la valeur du pH du sang en utilisant des capteurs optiques, p.ex. des oxymètres à photométrie spectrale invasifs, p.ex. introduits dans le corps par un cathéter

Abrégé

An element for the amplification of a light by stimulated emission of radiation comprising: a piece of glass with a tubular structure formed therein to guide light; the tubular structure has a boundary region of average refractive index less than that of a majority of the piece of glass; and a plurality of centres in the piece of glass that amplify the guided light, the amplification being by stimulated emission of radiation when the centres are illuminated by another light. Also contemplated is a method of manufacturing said element that comprises the step of: translating a focal point of an electromagnetic radiation relative to a piece of glass to form a tubular structure to guide light, that has a boundary region of average refractive index less than that of a majority of the piece of glass, determined, at least in part, by the interaction between the electromagnetic radiation and glass.

Classes IPC  ?

• H01S 3/063 - Lasers à guide d'ondes, p.ex. amplificateurs laser
• H01S 3/091 - Procédés ou appareils pour l'excitation, p.ex. pompage utilisant le pompage optique
• H01S 3/17 - Matériaux solides amorphes, p.ex. verre

Abrégé

The present disclosure provides a CXCR4-CCR7 heteromultimer, molecules that bind thereto and/or modulate function thereof and uses therefor.

Classes IPC  ?

• C07K 14/715 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire pour des interférons
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
• A61K 38/00 - Préparations médicinales contenant des peptides
• C07K 1/00 - Procédés généraux de préparation de peptides
• G01N 33/53 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet

Abrégé

The present disclosure provides a method of characterising a dielectric material. The method comprises the step of providing a light source, a light collector and a sensor. The sensor is arranged so that an evanescent field of light penetrates through a surface of the sensor and surface plasmons are generated at the surface of the sensor when suitable light is directed along at least a portion of the sensor. The method also includes the step of exposing the surface of the sensor to the dielectric material so that an interface is formed between the surface and the dielectric material. Further, the method comprises guiding light along at least a portion of the sensor to generate the surface plasmons. In addition, the method comprises the step of collecting an intensity of light from the interface as a function of a spectral parameter of the light. Further, the present disclosure provides an apparatus for characterising the dielectric material in accordance with the method.

Classes IPC  ?

• G01N 21/25 - Couleur; Propriétés spectrales, c. à d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes
• G02B 6/00 - OPTIQUE ÉLÉMENTS, SYSTÈMES OU APPAREILS OPTIQUES - Détails de structure de dispositions comprenant des guides de lumière et d'autres éléments optiques, p.ex. des moyens de couplage

Abrégé

The present invention relates to a method of producing an embryo from an oocyte by an assisted reproduction technology. The method includes (a) collecting an oocyte from an ovary of a subject in a collection medium comprising a first phosphodiesterase inhibitor and an agent that increases intracellular cAMP concentration in the oocyte, (b) culturing the oocyte in a maturation medium comprising a second phosphodiesterase inhibitor, and (c) producing an embryo from the oocyte by an assisted reproduction technology. The present invention also relates to methods of inducing oocyte maturation. For example a method of in vitro maturation of an oocyte is described which comprises steps (a) and (b) above. The present invention also relates to an oocyte maturation medium comprising a phosphodiesterase inhibitor and a ligand for inducing maturation of the oocyte. A combination product comprising an oocyte collection and maturation medium referred to above is also described.

Classes IPC  ?

• C12N 5/075 - Oocytes; Oogonies
• C12N 5/02 - Propagation de cellules individuelles ou de cellules en suspension; Leur conservation; Milieux de culture à cet effet

Abrégé

A method and system for assessing the condition of a pipe carrying a fluid is disclosed. The method includes the steps of generating a pressure wave in the fluid being carried along the pipe and detecting a pressure wave interaction signal resulting from an interaction of the pressure wave with a localised variation in pipe condition. The method then involves determining from the timing of the pressure wave interaction signal the location of the localised variation in pipe condition and the extent of the localised variation in pipe condition based on a characteristic of the pressure wave interaction signal.

Classes IPC  ?

• G01M 3/28 - Examen de l'étanchéité des structures ou ouvrages vis-à-vis d'un fluide par utilisation d'un fluide ou en faisant le vide par mesure du taux de perte ou de gain d'un fluide, p.ex. avec des dispositifs réagissant à la pression, avec des indicateurs de débit pour soupapes
• G01L 9/00 - Mesure de la pression permanente, ou quasi permanente d’un fluide ou d’un matériau solide fluent par des éléments électriques ou magnétiques sensibles à la pression; Transmission ou indication par des moyens électriques ou magnétiques du déplacement des éléments mécaniques sensibles à la pression, utilisés pour mesurer la pression permanente ou quasi permanente d’un fluide ou d’un matériau solide fluent
• G01L 11/00 - Mesure de la pression permanente, ou quasi permanente d'un fluide ou d'un matériau solide fluent par des moyens non prévus dans les groupes ou

Abrégé

The present invention relates to a method and kit for determining the likelihood of one or more complications of pregnancy occurring. The method and kit of the present invention are predicated on identifying the presence of one or more genetic polymorphisms associated with an increased likelihood of a pregnancy complication occurring in one or more of the subject, the maternal donor, the paternal donor, the fetus or the embryo.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The present invention relates to a method of preventing and/or treating a disease, condition or state associated with reduced dopaminergic neuron function in a subject. The method includes the step of administering to the subject an effective amount of a substance P receptor antagonist. The present invention also relates to the administration of a substance P receptor antagonist to a subject in methods for inhibiting progression of a disease, condition or state associated with reduced dopaminergic neuron function in the subject, or for alleviating one or more complications in the subject which are associated with administration of a dopaminergic agent. Pharmaceutical compositions and combination products which include a substance P receptor antagonist are also described.

Classes IPC  ?

• A61K 31/473 - Quinoléines; Isoquinoléines condensées en ortho ou en péri avec des systèmes carbocycliques, p.ex. acridines, phénantridines
• A61K 31/5355 - Oxazines non condensées contenant d'autres hétérocycles
• A61P 25/18 - Antipsychotiques, c. à. d. neuroleptiques; Médicaments pour le traitement de la manie ou de la schizophrénie
• A61K 31/46 - Aza-8-bicyclo[3.2.1]octane; Ses dérivés, p.ex. atropine, cocaïne
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• A61K 31/5377 - 1,4-Oxazines, p.ex. morpholine non condensées et contenant d'autres hétérocycles, p.ex. timolol
• A61P 25/16 - Antiparkinsoniens

Abrégé

The present invention is predicated, in part, on the determination of the crystal structure of Staphylococcus aureus biotin protein ligase. The present invention provides, among other things, the crystal structure of Staphylococcus aureus biotin protein ligase complexed with biotinyl 5'-adenylate at a resolution of 2.6 Angstroms. Accordingly, the present invention also provides methods for the identification and/or rational design of antagonists and agonists of biotin protein ligase enzymes, and in particular, antagonists of Staphylococcus aureus biotin protein ligase. Such antagonists may be used to inhibit bacterial infections, including Staphylococcus aureus infections.

Classes IPC  ?

• C07K 14/315 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de bactéries provenant de Streptococcus (G), p.ex. Enterocoques
• C12Q 1/25 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des enzymes qui ne peuvent pas être classées dans les groupes
• C12N 9/00 - Enzymes, p.ex. ligases (6.); Proenzymes; Compositions les contenant; Procédés pour préparer, activer, inhiber, séparer ou purifier des enzymes

Abrégé

The present inventions relates to a method and composition for modulating androgen receptor activity. The present invention arises out of studies into the regulation of androgen receptor activity. In the present studies it has been found that the small glutamine-rich tetratricopeptide repeat containing protein alpha (αSGT) modulates androgen receptor activity. Modulating the level and/or activity of αSGT modulates androgen receptor activity.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
• A61K 38/17 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains

Abrégé

An avian embryo model system is disclosed which provides an assay for investigating cellular and molecular mechanisms of neuroplasticity induced by stem/precursor cells and/or the effect of various agents (including stem/precursor cells) on neuronal development.

Classes IPC  ?

• G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• C07K 14/00 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
• C07K 4/00 - Peptides ayant jusqu'à 20 amino-acides dans une séquence indéterminée ou partiellement déterminée; Leurs dérivés
• C12N 15/00 - Techniques de mutation ou génie génétique; ADN ou ARN concernant le génie génétique, vecteurs, p.ex. plasmides, ou leur isolement, leur préparation ou leur purification; Utilisation d'hôtes pour ceux-ci

Abrégé

A sensor based on optical fiber technology is described. The sensor includes an elongate core for propagating light having an excitation wavelength; an interaction region that includes a fluorescent material for excitation by the propagated light to produce fluorescent light; and an interface region defining a boundary between the elongate core and the interaction region. The elongate core of the sensor is adapted to increase an intensity of the propagated light at the interface region to increase the amount of captured fluorescent light in the elongate core.

Classes IPC  ?

• G01N 21/64 - Fluorescence; Phosphorescence
• G02B 6/02 - Fibres optiques avec revêtement

Abrégé

The present invention relates generally to methods for reducing intracranial pressure in a subject. More particularly, the methods of the present invention include administering to the subject an effective amount of a substance P receptor antagonist.

Classes IPC  ?

• A61K 31/5375 - 1,4-Oxazines, p.ex. morpholine
• A61K 31/405 - Acides indole-alkanecarboxyliques; Leurs dérivés, p.ex. tryptophane, indométhacine
• A61K 31/445 - Pipéridines non condensées, p.ex. pipérocaïne
• A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p.ex. pipérazine
• A61K 38/00 - Préparations médicinales contenant des peptides
• A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p.ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénal
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux

Abrégé

A method for generating a three dimensional (3D) model of an object from a series of two dimensional (2D) images is described. The series of 2D images depict varying views of the object and have associated camera parameter information. The method includes the steps of tracing the object in a first 2D image selected from the series of 2D images to provide a first set of tracing information, then tracing the object in a second 2D image selected from the series of 2D images to provide a second set of tracing information. The 3D model of the object is then generated based on the camera parameter information and the first and second sets of tracing information.

Classes IPC  ?

• G06T 17/20 - Description filaire, p.ex. polygonalisation ou tessellation

Abrégé

The present invention relates to methods for determining the genetic origin of the mitochondrial genome of a cell. The present invention also relates to methods for identifying an organism with a mitochondrial genome of different genetic origin to the nuclear genome.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

A method for generating a population of functional regulatory T cells (TREG- cells), which are a subset of the T cell lineage having the ability to actively suppress immune activation and maintain peripheral immune tolerance, is described. The method comprises the steps of first culturing haemopoietic stem cells (HSC) and/ or haemopoietic progenitor cells in the presence of a Notch ligand that supports T cell differentiation, and then isolating T cells having a TREG-cell surface marker phenotype. A suitable source of HSC is cord blood (CB) and a suitable culture medium is OP9 cells engineered to express the Notch Ligand Delta-Like 1 (DL1) (OP9-DL1 cell line). Examples of TREG-cell surface marker phenotypes are CD4+CD25+, CD45RO+, CD45RA+, CD127Low-, LAG-3 and/ or CD39+.

Classes IPC  ?

• C12N 5/0783 - Cellules T; Cellules NK; Progéniteurs de cellules T ou NK
• A61K 35/12 - Substances provenant de mammifères; Compositions comprenant des tissus ou des cellules non spécifiés; Compositions comprenant des cellules souches non embryonnaires; Cellules génétiquement modifiées

Abrégé

The present invention relates a method of preventing and/or reducing an inflammatory response and/or inflammation in one or more tissues. The method includes delivering to the one or more tissues an effective amount of a substance P receptor antagonist.

Classes IPC  ?

• A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques 
• A61K 31/405 - Acides indole-alkanecarboxyliques; Leurs dérivés, p.ex. tryptophane, indométhacine
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]

Abrégé

The present invention relates to a method of preventing and/or reducing reperfusion injury to a tissue, organ, or organ system in a subject. The method includes administering to the subject an effective amount of a substance P receptor antagonist.

Classes IPC  ?

• A61K 31/405 - Acides indole-alkanecarboxyliques; Leurs dérivés, p.ex. tryptophane, indométhacine
• A61K 38/43 - Enzymes; Proenzymes; Leurs dérivés
• A61P 7/02 - Agents antithrombotiques; Anticoagulants; Anti-agrégants plaquettaires
• A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques 
• A61K 38/49 - Urokinase; Activateur du plasminogène
• A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p.ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénal

Abrégé

A method for estimating the activity topology of a set of sensed data windows is described. Each of the sensed data windows related to a corresponding sensed region. The method includes the steps of determining a subset of sensed data windows that are not connected; and excluding the subset of sensed data windows from the set of sensed data windows. In one embodiment, the sensed data windows corresponding to image windows such as would be provided by a visual surveillance system.

Classes IPC  ?

• H04N 7/18 - Systèmes de télévision en circuit fermé [CCTV], c. à d. systèmes dans lesquels le signal vidéo n'est pas diffusé

Abrégé

The present invention relates generally to transcriptional control sequences and the present invention is predicated, in part, on the identification of transcriptional control sequences which are derived from ARO1 genes. In some embodiments, the present invention relates to transcriptional control sequences that specifically or preferentially direct expression of a nucleotide sequence of interest in a plant gametophyte.

Classes IPC  ?

• C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p.ex. cellules transformées par des virus
• C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales

Abrégé

The present invention provides a method of isolating a pluripotent cell from a pre-implantation embryo without isolation of the pluripotent cells from other cells, the method including propagating a whole pre-implantation embryo including one or more pluripotent cells, embedded in a feeder cell layer and cultivated in a medium substantially free of serum, and isolating a pluripotent cell from the one or more pluripotent cells. The present invention also provides pluripotent cells generated by the method and uses thereof.

Classes IPC  ?

• C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
• C12N 5/0735 - Cellules souches embryonnaires; Cellules germinales embryonnaires

Abrégé

The invention discloses a method and system for analysing fluid flow within a body, and in particular the analysis of blood flow within the heart. Fluid sensitive images of the body may be obtained using a variety of mechanisms, including magnetic resonance imaging (MRI) technology. A motion estimation algorithm (such as an optical flow algorithm) is then applied to the images to produce a motion field. This can then be used to quantify the flow of the fluid within the body - in particular, various measures of non-linear blood flow are calculated such as shear strain, normal strain and v&ogr;rticity, for various locations within the body. These can then be displayed to a user (such as a cardiologist) by superimposing representations of the calculated measures onto an image of the body.

Classes IPC  ?

• A61B 5/026 - Mesure du débit sanguin
• A61B 5/02 - Mesure du pouls, du rythme cardiaque, de la pression sanguine ou du débit sanguin; Détermination combinée du pouls, du rythme cardiaque, de la pression sanguine; Evaluation d'un état cardio-vasculaire non prévue ailleurs, p.ex. utilisant la combinaison de techniques prévues dans le présent groupe et des techniques d'électrocardiographie; Sondes cardiaques pour mesurer la pression sanguine

Abrégé

The present invention relates to a method of treating Stage IV melanoma in a subject. The method includes the step of administering to the subject a therapeutically effective amount of a melanoma cell lysate and/or an immunotherapeutic extract, component or antigen thereof.

Classes IPC  ?

• A61K 35/12 - Substances provenant de mammifères; Compositions comprenant des tissus ou des cellules non spécifiés; Compositions comprenant des cellules souches non embryonnaires; Cellules génétiquement modifiées
• A61K 38/02 - Peptides à nombre indéterminé d'amino-acides; Leurs dérivés
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 35/00 - Agents anticancéreux
• A61P 37/04 - Immunostimulants

Abrégé

The present invention relates generally to transcriptional control sequences. Generally, the present invention relates to transcriptional control sequences that specifically or preferentially direct expression of a nucleotide sequence of interest in a plant egg cell. The present invention is predicated, in part, on the identification of transcriptional control sequences derived from EC1 genes which, in preferred embodiments, direct preferential expression in an egg cell of at least one plant taxon.

Classes IPC  ?

• C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
• A01H 4/00 - Reproduction de plantes par des techniques de culture de tissus
• C12N 15/29 - Gènes codant pour des protéines végétales, p.ex. thaumatine
• A01H 1/00 - Procédés de modification des génotypes
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p.ex. cellules transformées par des virus

Abrégé

The present invention relates to an antibody to insulin-like growth factor I receptor, or an antigen-binding portion of the antibody. The antibody, or the antigen-binding portion, bind to an epitope located in the cysteine-rich domain of the &agr;-subunit of the insulin-like growth factor I receptor, and the antibody or the antigen-binding portion modulates IGF-I mediated proliferation of an IGF-I dependent cell.

Classes IPC  ?

• C07K 16/22 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de croissance
• A61K 39/395 - Anticorps; Immunoglobulines; Immunsérum, p.ex. sérum antilymphocitaire
• A61P 35/00 - Agents anticancéreux
• C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p.ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
• C07K 16/30 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression

Abrégé

The present invention relates generally to quantitative trait loci (QTL) in animals. More particularly, the present invention relates to QTL for improved feed efficiency, measured as net feed intake, in bovine animals. The QTL identified in accordance with the present invention represent regions of the bovine genome where genetic variation is correlated with the level of feed intake and/or net feed intake in bovine animals.

Classes IPC  ?

• G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
• A01K 67/00 - NÉCESSITÉS COURANTES DE LA VIE ÉLEVAGE; CHASSE; PIÉGEAGE; PÊCHE ÉLEVAGE; AVICULTURE; APICULTURE; PISCICULTURE; PÊCHE; OBTENTION D'ANIMAUX, NON PRÉVUE AILLEURS; NOUVELLES RACES D'ANIMAUX Élevage ou obtention d'animaux, non prévus ailleurs; Nouvelles races d'animaux
• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The present invention relates to a method of modulating repair of a wound. The method includes modulating expression and/or activity of Flightless I in cells involved in repair of the wound.

Classes IPC  ?

• A61K 39/395 - Anticorps; Immunoglobulines; Immunsérum, p.ex. sérum antilymphocitaire
• A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
• A61K 38/02 - Peptides à nombre indéterminé d'amino-acides; Leurs dérivés
• A61K 38/43 - Enzymes; Proenzymes; Leurs dérivés
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
• A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
• C12N 5/22 - Cellules humaines
• C12N 15/12 - Gènes codant pour des protéines animales
• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
• C12N 15/87 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p.ex. co-transformation

Abrégé

The present invention relates generally to methods and transcriptional control sequences suitable for effecting expression of a nucleotide sequence of interest in a plant. More particularly, the present invention relates to methods and transcriptional control sequences suitable for directing specific or preferential expression of a nucleotide sequence of interest in a plant seed. Of particular interest as a transcriptional control sequence in this invention is the promoter PR602 (SEQ ID NO: 1) found in the 5 '-untranslated region of the rice ENDl-like gene and isolated from a rice panicle library.

Classes IPC  ?

• C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
• A01H 1/06 - Procédés de mutation, p.ex. traitements par produits chimiques ou irradiations
• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression

Abrégé

The present invention relates generally to polysaccharide synthases. More particularly, the present invention relates to (1,3;1,4)-beta-D-glucan synthases. The present invention provides, among other things, methods for influencing the level of (1,3;1,4)-beta-D-glucan produced by a cell and nucleic acid and amino acid sequences which encode (1,3;1,4)-beta-D-glucan synthases.

Classes IPC  ?

• C12N 15/29 - Gènes codant pour des protéines végétales, p.ex. thaumatine
• C12N 9/42 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2) agissant sur les liaisons bêta-glucosidiques-1, 4, p.ex. cellulase

Abrégé

The present invention relates to an oocyte and/or embryo culture medium. The medium includes 0.0003 to 750 ng/ml IGF-II, or a variant or analogue thereof, and further includes either or both of 0.01 to 50 騜g/ml plasminogen, or a variant or analogue thereof, and 0.01 to 50 騜g/ml urokinase plasminogen activator, or a variant or analogue thereof.

Classes IPC  ?

• C12N 5/02 - Propagation de cellules individuelles ou de cellules en suspension; Leur conservation; Milieux de culture à cet effet
• A61K 38/30 - Facteurs de croissance analogues à l'insuline (Somatomédines), p.ex. IGF-1, IGF-2
• C12N 5/075 - Oocytes; Oogonies

Abrégé

The present invention relates to a method of modulating apoptosis of a granulosa cell. The method includes one or more of the following steps: (i) modulating the concentration and/or activity of BMP-15 and/or BMP-6 that the granulosa cell is exposed to; (ii) modulating activity of a BMP-15 dependent signalling pathway in the granulosa cell; and (iii) modulating activity of a BMP-6 dependent signalling pathway in a granulosa cell.

Classes IPC  ?

• A61K 38/18 - Facteurs de croissance; Régulateurs de croissance
• A61K 38/22 - Hormones
• A61K 8/00 - Cosmétiques ou préparations similaires pour la toilette
• A61P 15/08 - Médicaments pour le traitement des troubles génitaux ou sexuels; Contraceptifs pour les troubles gonadiques ou pour augmenter la fertilité, p.ex. inducteurs d'ovulation ou de spermatogénèse
• C12N 5/075 - Oocytes; Oogonies

Abrégé

The present invention relates to a method of inhibiting a virus infection in a subject. The method includes the step of administering to the subject an antiviral agent, a nucleic acid vaccine expressing an antigen of the virus, and a second vaccine including an antigen of the virus.

Classes IPC  ?

• A61K 39/29 - Virus de l'hépatite
• A61K 31/711 - Acides désoxyribonucléiques naturels, c. à d. contenant uniquement des 2'-désoxyriboses liés à l'adénine, la guanine, la cytosine ou la thymine et ayant des liaisons 3'-5' phosphodiester
• A61P 31/12 - Antiviraux

Abrégé

A magnetically actuated valve is provided having a body with at least first and second orifices. The valve includes a magnetic actuating means having first and second valve members each associated with a respective magnetic field, the interaction of the magnetic fields being such that the valve members are normally urged away from each other to close the first and second orifices respectively. The magnetic actuating means also includes at least one supplementary magnetic field capable of interacting with either or both of the first and second magnetic fields to move one or both of the valve members to open a respective orifice.

Classes IPC  ?

• F16K 31/06 - Moyens de fonctionnement; Dispositifs de retour à la position de repos magnétiques utilisant un aimant
• B25J 11/00 - Manipulateurs non prévus ailleurs
• F16K 31/10 - Moyens de fonctionnement; Dispositifs de retour à la position de repos magnétiques utilisant un aimant avec mécanisme additionnel entre l'armature et l'élément de fermeture
• B25J 9/20 - Commandes à programme à fluide
• F16K 31/08 - Moyens de fonctionnement; Dispositifs de retour à la position de repos magnétiques utilisant un aimant utilisant un aimant permanent

Abrégé

The present invention relates to a method of modulating cardiac rhythm in a human subject. The method includes the step of modulating the activity of TREK-I and/or TREK-2 in the heart of the subject.

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains
• A61P 9/06 - Antiarythmiques
• C12N 5/16 - Cellules animales
• A01K 67/027 - Nouvelles races de vertébrés
• C07K 14/435 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains

Abrégé

The present invention relates to a method for identifying an inhibitor of a biotin protein ligase. The method include the steps of (a) providing a substrate, wherein the substrate may be biotinylated; (b) contacting the substrate with biotin and a biotin protein ligase in the presence of a test compound; (c) determining the extent of biotinylation of the substrate by the biotin protein ligase in the presence of the test compound; and (d) identifying the test compound as an inhibitor of the biotin protein ligase by a reduction in the biotinylation of the substrate in the presence of the test compound as compared to the extent of biotinylation of the substrate in the absence of the test compound.

Classes IPC  ?

• C12Q 1/25 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des enzymes qui ne peuvent pas être classées dans les groupes
• A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques 
• C12N 9/00 - Enzymes, p.ex. ligases (6.); Proenzymes; Compositions les contenant; Procédés pour préparer, activer, inhiber, séparer ou purifier des enzymes
• C12N 9/99 - Inactivation des enzymes par traitement chimique

Abrégé

A high speed optoelectronic analogue to digital converter using threshold logic circuits.

Classes IPC  ?

• H03M 1/12 - Convertisseurs analogiques/numériques
• H03K 19/08 - Circuits logiques, c. à d. ayant au moins deux entrées agissant sur une sortie; Circuits d'inversion utilisant des éléments spécifiés utilisant des dispositifs à semi-conducteurs

Abrégé

This invention relates to a method of preventing and/or treating a disease or condition associated with damage mediated by an -unsaturated aldehyde in a subject, the method including the step of administering to the subject a therapeutically effective amount of a hydrazino compound.

Classes IPC  ?

• A61K 31/15 - Oximes (C=N-O-); Hydrazines ( N-N); Hydrazones (N-N=)
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence